If you’ve been following our series on Cell & Gene Therapy, you’ll have read articles which span the full process from clinics to apheresis and viral vectors.
Here, we dive deep into the challenges of manufacturing, packaging and storage, through the prism of CAR-T therapies, which genetically modify the patient’s own T-cells to recognize and attack cancer cells.
Given its complexity, CAR-T presents significant challenges throughout the supply chain. Not only can mistakes be costly but, because each batch is custom-made and tailored to the patient, they can result in life-threatening delays to treatment.
How Are CAR-Ts Manufactured?
On arrival, the apheresis material is checked for temperature excursions and cell viability, highlighting the importance of the logistics discussed in our blog on apheresis. Even where temperature excursions or low cell viability are identified, manufacturers often proceed because a second apheresis procedure could be too demanding for the patient. If it has not already been processed upstream, the apheresis material is refined to isolate peripheral blood mononuclear cells (PBMCs), including T-cells, B-cells, NK-cells and monocytes, while removing unwanted cells.
The next step is optional T-cell enrichment. T-cells may account for 20–60% of the PBMC population; magnetic bead separation can increase this proportion to 80–95%. Whether enrichment is used or not, the T-cells are then activated to stimulate division and enable the viral vector (RVV or LVV) to introduce the DNA encoding the chimeric antigen receptor (CAR). This genetic modification turns the T-cells into CAR-T cells, equipping them to target cancer cells.
Then comes expansion. CAR-T cells are housed in bioreactors with growth media for 7-14 days, increasing in that time to billions. Cell therapy companies are increasingly slashing that timeline, which means faster therapies for patients on borrowed time, plus more manufacturing capacity. Post-expansion, cells are harvested – typically, spun or filtered – washed, then resuspended in cryoprotectant (5-10% DMSO). From there, the CAR-T cells are filled into infusion bags and placed in aluminum cassettes, where they’re frozen in a controlled rate freezer (CRF) to ≤-150°C.
That’s where packaging and logistics are vital, because the cassettes and bags are both critical and complicated to protect – labels can peel, corners can chip, bags can crack.
Label Application of Cryopreserved CAR-Ts
Labeling for cryogenic applications is complex. A label is applied to a CAR-T’s primary packaging before the controlled rate freezer (CRF) kicks in because adhesive won’t apply post-freeze. However, labels can easily peel off during the cryogenic process, which can become a serious regulatory problem.
In order to avoid this situation, the right adhesive must be selected - typically, a rubber-based adhesive for flexible bags and an acrylic-based adhesive for cassettes. From there, definition of correct label application process is imperative, as even small changes to an established routine can render labels ineffective.
As an example, hydrogen peroxide-based cleaning agents are a common sterilizing standby used to swab and sanitize materials in biopharma manufacturing. Unfortunately, hydrogen peroxide is also highly effective at stripping adhesives, and therefore, if applied to the bags or cassettes, could cause labels to become unstuck.
Another risk is any pre-chilling of cassettes before they are filled with the final product. Whilst this could seem logical, it also poses the potential for condensation, which could again impact label adhesion.
Essentially, it is vital to scope the critical-to-quality steps for keeping labels in place. Solid, documented proof is especially important when it comes to ensuring that the manufacturing team abides by these steps, even whilst under pressure to deliver greater speed and efficiency.
A further concern is label chipping at the corners of a casette, which can disrupt the necessary Chain of Identity. This most often occurs when material handlers are dealing with LN2 freezer racks. If sufficient care isn’t taken whilst looking for a specific cassette, the label corners can be chipped from neighboring cassettes. Again, the best way to prevent these incidents is to maintain rigorous standards of training and documentation – to establish best practice with a view to protecting packaging and labelling.
Bag breakages are another risk during the handling process, which will require costly and time-consuming CRF revalidation. The key is to plan to add cushioning systems into the cassettes with the bags, to mitigate against breakages. Even with process control and training, cushioning acts as a safety net, both at the manufacturing site but also the infusion site.
In short, CAR-T is highly personal, expensive, and leaves no margin for errors. CCT has the experience and portfolio to provide effective fixes, from process improvements to ensure reliable label adhesion, training to educate handlers, and cushioning to minimise the risk of breakage.